Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: A childrens cancer group phase III trial

Journal of Clinical Oncology

Volumn 11, Issue 3, 1993, Pages 527-537

  Tubergen, David G ^b   Gilchrist, Gerald S ^b   O'Brien, Richard T ^b   Coccia, Peter F ^b   Sather, Harland N ^b   Waskerwitz, Mary J ^b   Hammond, G Denman ^a  

^a CHILDREN S ONCOLOGY GROUP   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CD24 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BONE MARROW EXAMINATION; CANCER RISK; CEREBROSPINAL FLUID EXAMINATION; CHILD; CHILDHOOD CANCER; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; LIFE TABLE; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SEX; SKULL IRRADIATION; SURVIVAL RATE;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMAN; INFANT; INJECTIONS, SPINAL; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LIFE TABLES; MALE; METHOTREXATE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SUPPORT, U.S. GOV'T, P.H.S.; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0027406656     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1993.11.3.527     Document Type: Article

References (29)

1. Crist WM, Grossi CE, Pullen DJ, et al: Immunologic markers in childhood acute lymphocytic leukemia. Semin Oncol 12:105-121, 1985
2. Champlin R, Gale RP: Acute lymphoblastic leukemia: Recent advances in biology and therapy. Blood 73:2051-2066, 1989
3. Hammond D, Sather H, Nesbit M, et al: Analysis of prognostic factors in acute lymphoblastic leukemia. Med Pediatr Oncol 14:124-134, 1986
4. Bleyer WA, Sather H, Coccia P, et al: The staging of childhood acute lymphoblastic leukemia: Strategies of Children's Cancer Study Group and a three-dimensional technic of multivariate analysis. Med Pediatr Oncol 14:271-280, 1986
5. Abromowitch M, Ochs J, Pui CH, et al: Efficacy of high-dose methotrexate in childhood acute lymphocytic leukemia: Analysis of contemporary risk classifications. Blood 71:866-869, 1988
6. Riehm H, Gadner H, Henze G, et al: Acute lymphoblastic leukemia: Treatment results in three BFM studies (1970-1981), in Murphy SB, Gilbert JR (eds): Leukemia Research: Advances in Cell Biology and Treatment, New York, NY Elsevier Biomedical, 1983, pp 251-260
7. Aur JA, Simone J, Hustu HO, et al: Central nervous system therapy and combination chemotherapy of childhood lymphocytic leukemia. Blood 37:272-281, 1971
8. Bleyer WW, Poplack DG: Prophylaxis and treatment of leukemia in the central nervous system and other sanctuaries. Semin Oncol 12:131-148, 1985
9. Packer RJ, Meadows AT, Rorke LB, et al: Long-term sequelae of cancer treatment on the central nervous system in childhood. Med Pediatr Oncol 15:241-253, 1987
10. Ochs JJ: Neurotoxicity due to central nervous system therapy for childhood leukemia. Am J Pediatr Hematol Oncol 11:93-105, 1989
11. Littman P, Coccia P, Bleyer WA, et al: Central nervous system (CNS) prophylaxis in children with low risk acute lymphoblastic leukemia (ALL). Int J Radial Oncol Biol Phys 13:1443-1449, 1987
12. Sullivan MP, Chen T, Dyment PG, et al: Equivalence of intrathecal chemotherapy and radiotherapy as central nervous system prophylaxis in children with acute lymphatic leukemia: A Pediatric Oncology Group study. Blood 60:948-958, 1982
13. Hammond D, Sather H, Nesbit M, et al: Analysis of prognostic factors in acute lymphoblastic leukemia. Med Pediatr Oncol 14:124-131, 1986
14. Gaynon PS, Bleyer WA, Steinherz PG, et al: Modified BFM therapy for children with previously untreated acute lymphoblastic leukemia and unfavorable prognostic features. Am J Pediatr Hematol Oncol 10:42-50, 1988
15. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
16. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
17. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient, II. Analysis and examples. Br J Cancer 35:1-39, 1977.
18. Gail M, Simon R: Testing for qualitative interactions between treatment effects and patient subsets. Biometrics 41:361-372, 1985
19. Pike MC: Contribution to the discussion on the paper by R Peto and J Peto, "Asymptotically efficient rank invariant test procedures." J R Stat Soc A 135:201-203, 1972
20. Makuch RW, Simon MR: Sample size requirements for comparing time-to-failure among k treatment group. J Chronic Dis 35: 861-867, 1982
21. Goldie JH, Coldman AJ: The genetic origin of drug resistance in neoplasms: Implications for systemic therapy. Cancer Res 44:3643-3653, 1984
22. Norton L, Simon R: Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 61:1307-1317, 1977
23. Henze G, Fengler R, Reiter A, et al: Impact of early intensive reinduction therapy on event-free survival in children with low-risk acute lymphoblastic leukemia. Haematol Bluttranfus 33:483-488, 1990
24. Freiman J, Chalmere T, Smith H, et al: The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. N Engl J Med 299:690-694, 1978
25. Yusuf S, Collins R, Peto R: Why do we need some large, randomized trials? Stat Med 3:409-420, 1984
26. Freedman L: The size of clinical trials in cancer research - What are the current needs? Br J Cancer 59:396-400, 1989
27. Peto R: Clinical trial methodology. Biomedicine 28:24-36, 1978
28. Byar D, Piantadosi S: Factorial designs for randomized clinical trials. Cancer Treat Rep 69:1055-1063, 1985
29. Stampfer M, Buring J, Willett W, et al: The 2 × 2 factorial design: Its application to a randomized trial of aspirin and carotene in U.S. physicians. Stat Med 4:111-116, 1985